Trial Profile
An Open-label, Dose-escalation, Bi-weekly Phase I Clinical Trial in Treating Patients With Recurrent or Metastatic Cervical Cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Socazolimab (Primary)
- Indications Cervical cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Lee's Pharmaceutical
- 22 Sep 2022 Results published in the Clinical Cancer Research
- 07 Jun 2022 Results(n=104) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 10 May 2021 Planned number of patients changed from 15 to 110.